{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:20:40Z","timestamp":1779146440202,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.vaccine.2015.01.043","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T02:10:37Z","timestamp":1422411037000},"page":"1492-1498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso\u2014Implications for introduction of PsA-TT into the Expanded Programme on Immunization"],"prefix":"10.1016","volume":"33","author":[{"given":"Sarah A.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Ludovic","family":"Kambou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Goodson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Flannery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa\u00efe","family":"Medah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Messonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Diomande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoudou H.","family":"Djingarey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issaka","family":"Yameogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amadou","family":"Fall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Wannemuehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"50","key":"10.1016\/j.vaccine.2015.01.043_bib0115","first-page":"1022","article-title":"Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2015.01.043_bib0120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1377\/hlthaff.2011.0328","article-title":"Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine","volume":"30","author":"LaForce","year":"2011","journal-title":"Health Aff (Millwood)"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.01.043_bib0125","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","article-title":"Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","author":"Marc LaForce","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0130","series-title":"PsA-TT-007","author":"Registry P.A.C.T.","year":"2011"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0135","series-title":"Recensement G\u00e9n\u00e9ral de la Population et de l\u2019Habitation au Burkina Faso","author":"Institut National de la Statistique et de la D\u00e9mographie","year":"2010"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0140","series-title":"Recensement G\u00e9n\u00e9ral de la Population et de l\u2019Habitation au Burkina Faso","author":"Institut National de la Statistique et de la D\u00e9mographie","year":"2006"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0145","series-title":"Global measles and rubella strategic plan: 2012\u20132020","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0150","series-title":"Enqu\u00eate D\u00e9mographique et de Sant\u00e9 et \u00e0 Indicateurs Multiples du Burkina Faso 2010","author":"Institut National de la Statistique et de la D\u00e9mographie (INSD) et ICF International","year":"2012"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.01.043_bib0155","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1093\/infdis\/jir166","article-title":"The Americas: paving the road toward global measles eradication","volume":"204","author":"Castillo-Solorzano","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2015.01.043_bib0160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jama.1996.03530270064033","article-title":"Measles elimination in the Americas. Evolving strategies","volume":"275","author":"de Quadros","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0165","series-title":"Annuaire Statistique 2010","author":"Minist\u00e8re de la Sant\u00e9 du Burkina Faso, D.g.d.l.i.e.d.s.s.","year":"2011"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0170","series-title":"18th International Pathogenic Neisseria Conference","article-title":"Meningococcal A conjugate vaccine trial in infancy: a step towards routine immunization in the African meningitis belt","author":"Preziosi","year":"2012"},{"issue":"5","key":"10.1016\/j.vaccine.2015.01.043_bib0175","doi-asserted-by":"crossref","first-page":"e63605","DOI":"10.1371\/journal.pone.0063605","article-title":"Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt","volume":"8","author":"Tartof","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0180","series-title":"Introduction of a group A meningococcal conjugate vaccine in sub-Saharan Africa: cost\/savings analysis","author":"LaForce","year":"2008"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0185","series-title":"Human development report 2013\u2014the rise of the south: human progress in a diverse world","author":"United Nations Development Programme","year":"2013"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0190","series-title":"WHO-UNICEF estimates of MCV coverage","author":"Organization W.H.","year":"2013"},{"key":"10.1016\/j.vaccine.2015.01.043_bib0195","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2013 global summary. Last accessed: [January 11, 2014]; Available from: \u3008http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/estimates?c=BFA\u3009."},{"issue":"33","key":"10.1016\/j.vaccine.2015.01.043_bib0200","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1016\/j.vaccine.2012.05.024","article-title":"Measles outbreak in Burkina Faso, 2009: a case-control study to determine risk factors and estimate vaccine effectiveness","volume":"30","author":"Kidd","year":"2012","journal-title":"Vaccine"},{"issue":"9911","key":"10.1016\/j.vaccine.2015.01.043_bib0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2015.01.043_bib0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine: MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2015.01.043_bib0215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"Novak","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2015.01.043_bib0220","first-page":"129","article-title":"Meningococcal disease in countries of the African meningitis belt, 2012\u2014emerging needs and future perspectives","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Wkly Epidemiol Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T20:23:33Z","timestamp":1537907013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0264410X15000870"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso\u2014Implications for introduction of PsA-TT into the Expanded Programme on Immunization","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}